Skip to main content


Figure 1 | Diabetology & Metabolic Syndrome

Figure 1

From: Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Figure 1

Once daily injections of liraglutide delay body weight gain and obesity in corticosterone-exposed mice. Male C57Bl/6J mice were treated with 1% ethanol (Vehicle, white squares and circles or white bars) or 100 μg/ml corticosterone (GC, black squares and circles or black bars) via the drinking water together with once-daily injections of either PBS (squares or unstriped bars) or liraglutide (Lira) at a final dose of 0.3 mg per kg body weight (circles or striped bars) for five consecutive weeks (n = 6). Body weight gain (A) and food intake (B) was determined weekly, fat deposit size (C), and ectopic fat in liver (D and E) were determined after five weeks of treatment. Images in (D) are representative pictures of ORO staining in the examined tissue (20 × magnification, bar represents 150 μm). Data is shown as mean ± s.e.m. A * denotes a significant (p < 0.05) effect of corticosterone treatment and a # denotes a significant effect of liraglutide.

Back to article page